Clinical Trials
3
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Treatment of Long COVID Symptoms Utilizing Autologous Stem Cells Following COVID-19 Infection
Phase 1
Not yet recruiting
- Conditions
- Long COVID
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- American CryoStem Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT05669261
ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed Via Intravenous Infusion
Phase 1
Active, not recruiting
- Conditions
- Post-Concussion Syndrome
- Interventions
- Drug: 150 Adipose Derived Stem Cell InfusionDrug: 300 Adipose Derived Stem Cell InfusionDrug: Placebo InfusionDrug: 50 Adipose Derived Stem Cell Infusion
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- American CryoStem Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT04744051
- Locations
- 🇺🇸
BioSolutions Clinical Research Center, La Mesa, California, United States
Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis
Phase 1
Terminated
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2014-12-30
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- American CryoStem Corporation
- Target Recruit Count
- 2
- Registration Number
- NCT02326935
- Locations
- 🇰🇾
The Da Vinci Center, George Town, Cayman Islands
News
No news found